iCura Diagnostics takes great pride in offering state-of-the-art Circulating Tumor Cell (CTC) Services, built on the FDA-approved platform. Our CTC services are specifically designed to deliver cutting-edge capabilities for the detection and analysis of circulating tumor cells. With a strong focus on precision and reliability, our services enable researchers and medical professionals to gain valuable insights into cancer progression, treatment efficacy, and personalized medicine.
CTCs are shed tumor cells found in bodily fluids, holding crucial information about cancer biology, metastasis, and treatment response. Leveraging innovative technology, we capture, isolate, and analyze these rare CTCs, offering critical insights for treatment decisions and improved patient outcomes.
Our FDA-approved CTC platform enables precise detection and characterization, even at lower concentrations. Utilizing advanced techniques and instrumentation, we enhance sensitivity and specificity, ensuring accurate profiling and analysis.
For Clinical Trial Studies, our CTC Services support treatment efficacy assessment, disease progression monitoring, and predicting patient outcomes. By capturing CTCs throughout therapy, we analyze their molecular and genetic characteristics, refining treatment strategies, identifying therapeutic targets, and enabling personalized medicine approaches.
In Medical Diagnosis, our CTC Services provide a non-invasive alternative to tissue biopsies. Analyzing CTCs reveals diagnostic information like tumor subtype, genetic mutations, and prognostic markers. This approach avoids invasive procedures and allows monitoring for informed decision-making by clinicians and patients.
Adhering to regulatory standards, our CTC Services are performed under strict quality control and FDA compliance. Trustworthy and actionable results are our priority.
Leverage our FDA-approved CTC platform to confidently harness CTC analysis in your studies and clinical practice. Our dedicated team of experts delivers accurate and timely results, supporting cancer research advancements and improving patient care. Partner with iCura Diagnostics to unlock the transformative potential of CTC analysis for enhanced research and patient care
